Pioglitazone in Acute Ischemic Stroke Trial

Pioglitazone in Acute Ischemic Stroke Trial - Pioglitazone in Acute Ischemic Stroke Trial (PAIST)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000699

Enrollment

100

Registered

2008-12-31

Start date

2007-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Patients will be randomly selected to receive pioglitazone Patients will also be randomly selected to receive treatment with conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Admission within 7 days after the onset of ischemic stroke 2.Diabetes mellitus 3.cerebral thrombosis 4.NIHSS score 4-15

Exclusion criteria

Exclusion criteria: 1.cardiogenic embolism or cerebral hemorrhage 2.pregnancy 3.allergic to pioglitazone

Design outcomes

Primary

Measure	Time frame
NIH stroke scale score at 3 months	—

Secondary

Measure	Time frame
Recurrence of stroke and Cardiovascular event (cerebral hemorrhage, subarachnoid hemorrhage, myocardial infarction, angina pectoris, and ASO) within 3 months after starting treatment	—

Countries

Japan

Contacts

Public ContactHaruhiko Hoshino

Keio University School of Medicine Department of Neurology

hhoshino-keio@umin.ac.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026